Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight
London (PRWEB) November 19, 2013 -- Diabetes is one of the few disease areas that has retained its market value despite the entry of generics, the rise in drug prices and prevalence of the disease has allowed drug sales to soar to a worldwide value of $34.1 billion in 2012. While barriers to entry remain high with added scrutiny over cardiovascular and other safety risks, evident by Tresiba’s (insulin degludec; Novo Nordisk) recent US failure, the exponential market growth makes diabetes one of the most attractive opportunities in Pharma.
Competition in the major drug segments are intense with Sanofi’s basal insulin Lantus (insulin glargine), Novo’s prandial insulin NovoRapid/NovoLog (insulin aspart), Merck’s DPP-IV Januvia (sitagliptin), and Novo’s GLP-1 Victoza (liraglutide) leading the way in their respective classes with best in class efficacy and safety. In addition to these clinical advantages, more convenient administration devices and strong marketing has helped them stand out from the competition.
While Novo Nordisk, Sanofi and Merck look set to protect their franchises with exciting pipeline therapies, Key Opinion Leaders interviewed by FirstWord note that there are a number of unmet needs in diabetes treatment and management. Companies that can address these needs and differentiate their products from existing players will see significant traction in this lucrative indication. This is evident from the successful launches of the novel SGLT-2 inhibitors- Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) and Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca), in the US and EU. In addition, therapies showing significant incremental advances also have potential to usurp market share from the gold standard treatments.
‘Therapy Trends: Diabetes’ is compiled from exclusive, in-depth interviews with the world’s leading Key Opinion Leaders in diabetes. It identifies and analyses the major factors, advances and trends currently influencing the diabetes treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future Diabetes management.
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the diabetes disease area, and their scientific standing and clinical experience. Our unique KOL scoring system identifies those thought leaders with the greatest insight into how diabetes clinical research will shape the future market.
Key Benefits
Diabetes: Battle for ascendancy escalates in expanding market examines the most prominent insights gained from the field’s key opinion leaders. The results of FirstWord’s research and analysis will help you to:
-Comprehend the current trends driving and shaping the global diabetes market
-Understand the future landscape and how new drug classes will fit into the treatment algorithm
-Compare and contrast the clinical profile of the insulins, DPP-IV, GLP-1 and SGLT-2 classes and assess their competitive strengths and weaknesses
-Assess the commercial and clinical potential of the next generation pipeline drugs, biosimilars, and existing therapies.
-Appreciate KOL calls for novel therapies and understand the commercial threat and opportunity for current products.
-Develop positioning strategies based on KOL insight
-Identify critical areas of unmet clinical need and opportunities for better disease management
-Evaluate the performance of companies with the most robust new product pipelines
-Recognise the key factors KOLs predict will drive future treatment trends
Critical questions answered
Diabetes: Battle for ascendancy escalates in expanding market answers key questions including:
-How might new therapies impact on the current first-line treatments?
-What are the current unmet needs and major challenges in diabetes treatment?
-What are the most promising late-stage classes in development?
-Which therapies are KOLs eagerly awaiting?
-How will the new therapies be positioned against each other in each of the disease segments?
-In what ways could players improve on existing therapies and what impact could this have on prescribing?
-How will treatment of diabetes look in the future?
-How do KOLs think the pricing environment is shaping the uptake of new diabetes treatments?
-What clinical research trends do KOLs predict for future diabetes therapies?
Diabetes Panel of Key Opinion Leaders
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the Diabetes disease area, and their scientific standing and clinical experience. The Diabetes KOL panel assembled for this Therapy Trends research is drawn from North America and Europe:
-Associate Professor of Endocrinology, University of Michigan, Ann Arbor, MI.
-Assistant Professor, Division of General Internal Medicines, John Hopkins University, Baltimore, MD.
-Clinical Associate Professor of Medicine, Division of General Internal Medicines, University of Washington School of Medicine, Washington.
-Director of the Clinical Diabetes Center at the University Hospital Albert Einstein College of Medicine, a Division of Montefiori Medical Center, NY
-Associate Professor of Medicine, Endocrinology and Metabolism, Duke University, Durham, NC.
-Professor of Endocrinology and Metabolic Diseases, University of Nantes; Head of the Internal Medicine, Endocrinology and Diabetes Department
-Honorary Consultant, Diabetes, University Hospital Leicester, Leicesteshire, UK
-Director, Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Basel, Switzerland.
-Professor, Professor of Medicine, Diabetes, Eberhard Karls University, University Hospital of Tuebingen, Germany.
-Professor of Medical Physiology, Department of Biomedical Sciences; Director of the Research Cluster for Diabetes and Obesity; Vice Chairman, Faculty of Health Sciences, University of Copenhagen, Denmark.
-Head, Diabeteszentrum Bad Lauterberg, Harz, Germany.
-Professor John Wilding, MD, Head of the Department of Obesity and Endocrinology, University of Liverpool, UK.
Future Event Updates
Dynamic clinical sectors develop. New product approvals/launches, extended indications or unexpected late-stage research failures/withdrawals can have a major impact on the treatment options for clinicians and performance of companies. What does such an event mean for stakeholders?
FirstWord’s Therapy Trends Future Event Updates keep you one step ahead. As soon as a significant event has been identified we contact our KOL panelists to get their perspective of the event and what it means. This data is incorporated into the report and re-issued so the event can be seen in its wider market context.
This valuable service is included in the purchase price of the report and is provided for 12 months. You will receive fresh analysis every time a major market event breaks and a fully updated report will be delivered by to you one our consultants within days of each event’s occurrence.
Whatever the event, Therapy Trends has the contacts, resources and knowledge to keep you up to date with what the latest market movements mean.
Methodology
This report provides a qualitative overview of the current and future diabetes market. Information was gathered from telephone interviews held with twelve key opinion leaders (KOLs), from across the major diabetes markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also influence the dynamics of Pharma markets in other countries.
In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.
Subjects covered in the interviews included future diagnostic and therapeutic strategies for diabetes, the future of diabetes drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing diabetes drug classes, the cost of newer drugs and other concerns in the therapy area.
Executive summary
Introduction
Methodology
Current diabetes marketplace
Diabetes overview
Diabetes definition
Diabetes segmentation
Epidemiology
Aetiology
Risk factors
Symptoms
Complications of diabetes
Diagnosis
Diabetes treatment
Current treatment landscape
Reimbursement of key diabetes brands
Current marketed therapies
Basal insulins
Prandial insulins
Premixed insulins
Dipeptidyl Peptidase-IV (DPP-IV) inhibitors
Glucagon-like peptide-1 (GLP-1) agonists/analogues
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
Thiazolidinediones (TZD)
Other non-insulin anti-diabetics
Pipeline therapies
Pipeline basal insulins
Pipeline prandial insulins
Pipeline dipeptidyl peptidase-IV (DPP-IV) inhibitors
Pipeline glucagon-like peptide-1 (GLP-1) agonists/analogues
Pipeline sodium-glucose co-transporter 2 (SGLT-2) inhibitors
Other pipeline non-insulin anti-diabetics
Treatment focus
Unmet needs in type 1 diabetes
Unmet needs in type 2 diabetes
Current treatment algorithm- Type2 diabetes
Future treatment algorithm
Future developments in Diabetes
KOL biographies
Read the full report:
Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article